SMART: Speed Manipulated Adaptive Rehabilitation Therapy Bike for Parkinson's Disease

Sponsor
Kent State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05361200
Collaborator
(none)
40
1
2
19.7
2

Study Details

Study Description

Brief Summary

Parkinson's disease (PD) is a progressive neurological disorder that results in slowness of movement, muscle stiffness, tremor, and postural instability. These symptoms significantly affect PD patients' quality of life, independence, and functional performance. There is currently no cure for PD, but symptoms can be treated with levodopa or deep brain stimulation surgery. Exercise-based rehabilitation has similar beneficial effects to surgical and pharmacological management without the potential negative side effects. Cycling-based interventions have been shown to increases motor function and mobility in individuals with PD. Specifically, benefits are greater when cycling cadence (revolutions per minute, RPM) is 30% greater than a self-selected pace.

Although high cadence cycling improves motor function in individuals with PD, there is significant heterogeneity in individual responses. To maximize the treatment effects and minimize the heterogeneity of high-cadence cycling, it is important to determine patient-specific settings. Previous studies have shown that higher variability (entropy) of cadence leads to greater improvement in motor function. The entropy of cadence calculation will be utilized to understand how patient-specific settings can drive improvements. The purpose of this study is to determine patient-specific settings and measure the effects of high cadence stationary (i.e. dynamic) cycling on functional performance in individuals with PD. Volunteers with Parkinson's disease will complete 12 cycling sessions over a 1-month period and measures of motor function, quality of life, functional performance, mood and exercise readiness will be collected.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Dynamic high-cadence cycling
N/A

Detailed Description

Potential participants will be prescreened with the ACSM pre-participation questionnaire over the phone or in person. Those who qualify will be asked to visit the research lab and sign the informed consent. Participants will be randomized into one of two groups: 1) patients-specific adaptive dynamic cycling or 2) non-adaptive dynamic cycling. Both groups will participate in a total of 12 sessions, each session consisting of 5 minutes of warm-up, 30 minutes of the main exercise, and 5 minutes of the cool-down period. For the patient-specific adaptive dynamic cycling group, the optimization process will be done after the 3rd, 6th, and 9th sessions. The optimization procedure is based on sample entropy of cadence calculation from the previous session's cycling performance. After optimization, participants will receive specific settings for the next session. For the non-adaptive group, individuals will cycle on the dynamic bike with pre-determined settings that will stay constant throughout the exercise protocol.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled study with 2 armsRandomized controlled study with 2 arms
Masking:
Single (Participant)
Masking Description:
Participant will not be told which group they were assigned to
Primary Purpose:
Treatment
Official Title:
Effects of Patient-Specific Adaptive Dynamic Cycling on Function Improvement in Individuals With Parkinson's Disease
Actual Study Start Date :
Apr 11, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Adaptive dynamic cycling

For the patient-specific adaptive dynamic cycling group, the optimization process will be done after the 3rd, 6th, and 9th sessions. The optimization procedure is based on sample entropy of cadence calculation from the previous session's cycling performance. After optimization, participants will receive specific settings for the next session.

Behavioral: Dynamic high-cadence cycling
Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
Other Names:
  • S.M.A.R.T. cycling
  • Active Comparator: Non-adaptive dynamic cycling

    For the non-adaptive group, individuals will cycle on the dynamic bike with pre-determined settings that will stay constant throughout the exercise protocol.

    Behavioral: Dynamic high-cadence cycling
    Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
    Other Names:
  • S.M.A.R.T. cycling
  • Outcome Measures

    Primary Outcome Measures

    1. Change in motor symptoms [4 weeks]

      MDS-UPDRS Motor III (Movement Disorders Society- Unified Parkinson's Disease Rating Scale) Minimum Score-0 Maximum Score- 138 Lower score represents improvement

    2. Change in motor kinematics [4 weeks]

      Kinesia One- Accelerometry

    Secondary Outcome Measures

    1. Change in quality of life [4 weeks]

      PDQ-39 (Parkinson' disease quality of life, 39 questions) Minimum Score- 0 Maximum Score- 156

    2. Change in mobility [4 weeks]

      Timed up and Go

    Other Outcome Measures

    1. Change in mood and affect [4 weeks]

      Mood and affective scales

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 79 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Idiopathic Parkinson's disease

    • 50-79 years of age

    • no contraindications to exercise including cardiovascular disease or stroke

    Exclusion Criteria:
    • one or more major signs/symptoms of cardiovascular or pulmonary disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kent State University Kent Ohio United States 44242

    Sponsors and Collaborators

    • Kent State University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Angela Ridgel, Professor, School of Health Sciences, Kent State University
    ClinicalTrials.gov Identifier:
    NCT05361200
    Other Study ID Numbers:
    • SMARTPD
    First Posted:
    May 4, 2022
    Last Update Posted:
    May 6, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Angela Ridgel, Professor, School of Health Sciences, Kent State University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 6, 2022